

LITERATURA

- Bakker T, Abu-Hanna A, Dongelmans DA, Vermeijden WJ, Bosman RJ, de Lange DW, et al. Clinically relevant potential drug-drug interactions in intensive care patients: A large retrospective observational multicenter study. *J Crit Care*. 2021 Apr;62:124-30.
- Wong A, Amato MG, Seger DL, Rehr C, Wright A, Slight SP, et al. Prospective evaluation of medication-related clinical decision support over-rides in the intensive care unit. *BMJ Qual Saf*. 2018 Sep;27(9):718-24.
- Fitzmaurice MG, Wong A, Akerberg H, Avramovska S, Smithburger PL, Buckley MS, et al. Evaluation of Potential Drug-Drug Interactions in Adults in the Intensive Care Unit: A Systematic Review and Meta-Analysis. *Drug Saf*. 2019 Sep 1;42(9):1035-44.
- Zheng WY, Richardson LC, Li L, Day RO, Westbrook JJ, Baysari MT. Drug-drug interactions and their harmful effects in hospitalised patients: a systematic review and meta-analysis. *Eur J Clin Pharmacol*. 2018 Jan 1;74(1):15-27.
- Hsiao SC, Lai WH, Chen IL, Shih FY. Clinical impact of carbapenems in critically ill patients with valproic acid therapy: A propensity-matched analysis. *Front Neurol*. 2023 Mar 9;14:1069742.
- Manc EE, Gidal BE. The effect of carbapenem antibiotics on plasma concentrations of valproic acid. *Ann Pharmacother*. 2009;43(12):2082-7.
- Al-Quteimat O, Laila A. Valproate Interaction With Carbapenems: Review and Recommendations. *Hosp Pharm*. 2020 Jun;55(3):181-7.
- Huang CR, Lin CH, Hsiao SC, Chen NC, Tsai WC, Chen SD, et al. Drug interaction between valproic acid and carbapenems in patients with epileptic seizures. *Kaohsiung J Med Sci*. 2017 Mar;33(3):130-6.
- Wen ZP, Fan SS, Du C, Yin T, Zhou BT, Peng ZF, et al. Drug-drug interaction between valproic acid and meropenem: a retrospective analysis of electronic medical records from neurosurgery inpatients. *J Clin Pharm Ther*. 2017;42(2):221-7.
- Doad G, McManus D, Topal J, Lopez F. 934: Utilizing the carbapenem-valproic acid drug interaction in the management of valproic acid overdose. *Crit Care Med*. 2018 Jan;46(1):450.
- Dreucean D, Beres K, McNierney-Moore A, Gravino D. Use of meropenem to treat valproic acid overdose. *Am J Emerg Med*. 2019 Nov 1;37(11):2120.e5-2120.e7.
- Cunningham D, Clark K, Lord K. Treatment of valproic acid overdose with meropenem in an epileptic patient. *Am J Emerg Med*. 2022 Mar;53:284.e1-284.e3.
- Thomas C, Priano J, Smith TL. Meropenem as an antidote for intentional valproic acid overdose. *Am J Emerg Med*. 2020 Mar;38(3):690.e1-690.e2.
- Teng R, Butler K. Effect of the CYP3A inhibitors, diltiazem and ketoconazole, on ticagrelor pharmacokinetics in healthy volunteers. *J Drug Assess*. 2013 Mar 15;2(1):30-9.
- Lexicomp® Drug Interactions [Internet]. UpToDate®. [cited 2023 Jul 20]. Available from: <http://uptodate.com/drug-interactions/>.
- Micromedex® Drug Interactions Results [Internet]. Merative Micromedex®. [cited 2023 Jul 20]. Available from: <http://micromedex.fnu.cz/micromedex2/librarian/PFDefault/evidencexpert.ShowDrugInteractionsResults>.
- Gurbel PA, Bliden KP, Butler K, Tantry US, Gesheff T, Wei C, et al. Randomized Double-Blind Assessment of the ONSET and OFFSET of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery Disease. *Circulation*. 2009 Dec 22;120(25):2577-85.
- Butler K, Teng R. Pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers. *Br J Clin Pharmacol*. 2010 Jul;70(1):65-77.
- Charpentier T, Ferdynus C, Lair T, Cordier C, Brulliard C, Valance D, et al. Bleeding risk of ticagrelor compared to clopidogrel in intensive care unit patients with acute coronary syndrome: A propensity-score matching analysis. *PLoS ONE*. 2020 May 4;15(5):e0232768.
- Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. *N Engl J Med*. 2009 Sep 10;361(11):1045-57.
- Azran M, Tanaka KA. Interaction Between Ticagrelor and CYP3A4 Inhibitor: Importance of P2Y12 Function Testing to Assess Platelet Recovery Before Surgery. *J Cardiothorac Vasc Anesth*. 2019 Nov 1;33(11):3221-2.
- Dobesh PP, Oestreich JH. Ticagrelor: Pharmacokinetics, Pharmacodynamics, Clinical Efficacy, and Safety. *Pharmacotherapy*. 2014 Oct;34(10):1077-90.
- Weeks P, Sieg A, Vahdat K, Raissi F, Nathan S. Improved Ticagrelor Antiplatelet Effect on Discontinuation of Phenytoin. *Ann Pharmacother*. 2014 May 1;48(5):644-7.
- Nutt JG, Woodward WR, Carter JH, Trotman TL. Influence of fluctuations of plasma large neutral amino acids with normal diets on the clinical response to levodopa. *J Neurol Neurosurg Psychiatry*. 1989 Apr 1;52(4):481-7.
- Deleu D, Northway MG, Hanssens Y. Clinical Pharmacokinetic and Pharmacodynamic Properties of Drugs Used in the Treatment of Parkinson's Disease. *Clin Pharmacokinet*. 2002 Apr 1;41(4):261-309.
- Cooper MK, Brock DG, McDaniel CM. Interaction between levodopa and enteral nutrition. *Ann Pharmacother*. 2008 Mar;42(3):439-42.
- Leta V, Klingelhofer L, Longardner K, Campagnolo M, Levent HÇ, Aureli F, et al. Gastrointestinal barriers to levodopa transport and absorption in Parkinson's disease. *Eur J Neurol*. 2023;30(5):1465-80.
- Bonnici A, Ruiner CE, St-Laurent L, Hornstein D. An interaction between levodopa and enteral nutrition resulting in neuroleptic malignant-like syndrome and prolonged ICU stay. *Ann Pharmacother*. 2010 Sep;44(9):1504-7.
- Whitman CB, Abiordepey E, Taylor B. Levodopa Withdrawal Presenting as Fever in a Critically Ill Patient Receiving Concomitant Enteral Nutrition. *J Pharm Pract*. 2016 Dec 1;29(6):574-8.
- Vogelzang JMJ, Luinstra M, Rutgers AWF. Effect of Rectal Levodopa Administration: A Case Report. *Case Rep Neurol*. 2015 Oct 21;7(3):209-12.
- Josková V, Linhartová A. Levodopa (+ inhibitor dekarboxylázy) [Internet]. Doporučení pro podání léčiv sondou. 2021 [cited 2023 Jul 22]. Available from: https://www.co-skf.cz/images/Dokumenty/Doporuzeni_sondy/levodopa_s_inhibitoaremddekarboxylazy_-_doporuen.pdf.
- VandenBerg A, Broadway J. Enteral administration of protein supplement and valproate: A potential pharmacokinetic interaction. *Ment Health Clin*. 2018 Mar 23;7(1):10-2.
- Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT. Recommendations for the use of medications with continuous enteral nutrition. *Am J Health Syst Pharm*. 2009 Aug 15;66(16):1458-67.
- Khatib R, Sabir FRN, Omari C, Pepper C, Tayebjee MH. Managing drug-induced QT prolongation in clinical practice. *Postgrad Med J*. 2021 Jul 1;97(1149):452-8.
- Tisdale JE, Jaynes HA, Kingery JR, Mourad NA, Trujillo TN, Overholser BR, et al. Development and Validation of a Risk Score to Predict QT Interval Prolongation in Hospitalized Patients. *Circ Cardiovasc Qual Outcomes*. 2013 Jul;6(4):479-87.
- Pickham D, Helfenbein E, Shinn JA, Chan G, Funk M, Weinacker A, et al. High prevalence of corrected QT interval prolongation in acutely ill patients is associated with mortality: Results of the QT in Practice (QTIP) Study. *Crit Care Med*. 2012 Feb;40(2):394.
- Indraratna P, Tardo D, Delves M, Szirt R, Ng B. Measurement and Management of QT Interval Prolongation for General Physicians. *J Gen Intern Med*. 2020 Mar 1;35(3):865-73.
- Elangovan A. QTc Prolongation in the Critically Ill: Tread with Caution! *Indian J Crit Care Med*. 2020 Apr;24(4):220-1.
- Ding Y, Jeon R, Ran L, Pan W, Wang F, Li Q. New-onset QT prolongation is a novel predictor of mortality in critically ill patients. *Crit Care*. 2019 Jun 21;23(1):229.
- Russell H, Churilov L, Toh L, Eastwood GM, Bellomo R. The incidence, predictors and outcomes of QTc prolongation in critically ill patients. *J Crit Care*. 2019 Dec 1;54:244-9.
- Javanainen T, Ishihara S, Gayat E, Charbit B, Jurkko R, Cinotti R, et al. Prolonged corrected QT interval is associated with short-term and long-term mortality in critically ill patients: results from the FROG-ICU study. *Intensive Care Med*. 2019 May 1;45(5):746-8.
- Shenthar J, Rachaiha JM, Pillai V, Chakali SS, Balasubramanian V, Chollenhalli Nanjappa M. Incidence of drug-induced torsades de pointes with intravenous amiodarone. *Indian Heart J*. 2017 Nov 1;69(6):707-13.
- QTDrugs Lists : Crediblemeds [Internet]. [cited 2023 Oct 15]. Available from: <https://crediblemeds.org/druglist>.
- Hasnain M, Vieweg WVR, Howland RH, Kogut C, Breden Crouse EL, Koneru JN, et al. Quetiapine, QTc interval prolongation, and torsade de pointes: a review of case reports. *Ther Adv Psychopharmacol*. 2014 Jun;4(3):130-8.
- Dube KM, DeGrado J, Hohlfelder B, Szumita PM. Evaluation of the Effects of Quetiapine on QTc Prolongation in Critically Ill Patients. *J Pharm Pract*. 2018 Jun;31(3):292-7.
- Zeppenfeld K, Tfelt-Hansen J, de Riva M, Winkel BG, Behr ER, Blom NA, et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. *Eur Heart J*. 2022 Oct 21;43(40):3997-4126.
- Grimm SW, Richtand NM, Winter HR, Stams KR, Reece SB. Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics. *Br J Clin Pharmacol*. 2006;61(1):58-69.
- Schulz-Du Bois C, Schulz-Du Bois AC, Bewig B, Gerstner I, Aldenhoff JB, Cascorbi I, et al. Major increase of quetiapine steady-state plasma concentration following co-administration of clarithromycin: confirmation of the pharmacokinetic interaction potential of quetiapine. *Pharmacopsychiatry*. 2008 Nov;41(6):258-9.
- Huang X, Zhou Y, Zhang J, Xiang H, Mei H, Liu L, et al. The importance of CYP2C19 genotype in tacrolimus dose optimization when concomitant with voriconazole in heart transplant recipients. *Br J Clin Pharmacol*. 2022;88(10):4515-25.
- Bakker T, Klopotoswska JE, de Keizer NF, van Marum R, van der Sijts H, de Lange DW, et al. Improving medication safety in the Intensive Care by identifying relevant drug-drug interactions - Results of a multicenter Delphi study. *J Crit Care*. 2020 Jun;57:134-40.